Lower Risks of Dementia, Stroke, and Mortality Associated with GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity
Recent research highlights that GLP-1 receptor agonists significantly decrease the risk of dementia, stroke, and death in individuals with type 2 diabetes and obesity, offering promising neuroprotective benefits beyond glucose management.
A recent study published in July 2025 in JAMA Network Open reveals that adults with type 2 diabetes and obesity who are treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) experience a significant reduction in the risks of developing dementia, ischemic stroke, and overall mortality compared to those on other diabetic medications. The research analyzed electronic health records of over 60,000 individuals, ensuring a balanced comparison between those using GLP-1 RAs such as semaglutide and tirzepatide and those on other antidiabetic drugs like metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, and alpha-glucosidase inhibitors.
Participants were followed over seven years, and the findings showed that users of GLP-1 RAs had hazard ratios indicating a lowered risk for dementia (0.63), ischemic stroke (0.81), and death from any cause (0.70). Notably, the protective effects were more pronounced among individuals aged 60 and above, women, and those with a body mass index ranging from 30 to 40. However, the study did not observe significant differences in the risks for Parkinson's disease or intracerebral hemorrhage.
The authors suggest that these outcomes point toward a potential role of GLP-1 RAs in reducing neurodegenerative and cerebrovascular risks in high-risk populations, emphasizing the importance of these medications not just for glycemic control but also for their broader neurological and cardiovascular benefits.
Source: https://medicalxpress.com/news/2025-07-dementia-ischemic-mortality-glp-receptor.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Breakthrough in Gene-Edited Islet Transplant Demonstrates Success in Human Trial
A groundbreaking human trial demonstrates that gene-edited islet cells can survive and function without immune suppression, offering new hope for type 1 diabetes treatment.
Increased Winter Child Mortality in England Revealed by New Research
New research shows a higher rate of child deaths in England during winter months, primarily driven by infections and socioeconomic factors. Learn more about these crucial findings.
Expanding Medicaid Coverage for Doulas in Republican-Led States Boosts Maternal and Infant Health
Many states, including GOP-led ones, are expanding Medicaid coverage to include doula services, improving maternal and infant health outcomes nationwide. Learn how bipartisan support and research-backed benefits are driving this change.
Feasibility of Large-Scale Neuroimaging Data Collection in Low-Income Communities
A new study demonstrates the successful and cost-effective collection of high-quality neuroimaging data in low- and middle-income communities, paving the way for more inclusive and scalable brain research.